研发创新
R&d innovation
-
First-in-human immunomodulation mechanism research of chlorogenic acid in patients with recurrent high-grade glioma
First-in-human immunomodulation mechanism research of chlorogenic acid in patients with recurrent high-grade glioma2018.04.27本研究首次探讨了绿原酸在复发性高级别胶质瘤患者中的免疫调节机制。研究纳入6例患者，收集其绿原酸治疗前后的外周血样本，通过高通量RNA测序（RNA-seq）分析基因表达差异。结果显示，2例患者（P3和P4）在绿原酸治疗后达到疾病稳定状态，无进展生存时间分别为8.1个月和4.9个月，总生存时间均为16.5个月，且至今仍存活。 -
Isolation and identification of human metabolites from a novel anti-tumor candidate drug 5-chlorogenic acid injection by HPLC-HRMS_MSn and HPLC-SPE-NMR
Isolation and identification of human metabolites from a novel anti-tumor candidate drug 5-chlorogenic acid injection by HPLC-HRMS_MSn and HPLC-SPE-NMR2017.09.20本研究对新型抗肿瘤药物注射用绿原酸在人体内的代谢产物进行了分离和鉴定。研究中，健康成年人肌肉注射该药后，收集其尿液和粪便样本进行分析。结果显示，粪便中未检测到代谢产物，而尿液中共鉴定出6种代谢产物，包括异构化绿原酸、水解绿原酸以及甲基化绿原酸（M3和M4），其中M3和M4为主要代谢产物。
-
Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype
Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype2017.01.05本文研究了绿原酸（CHA）通过将肿瘤相关巨噬细胞从促肿瘤的M2表型极化为抗肿瘤的M1表型，从而抑制胶质母细胞瘤生长的机制。研究发现，CHA通过促进STAT1信号通路激活和抑制STAT6信号通路激活来调节巨噬细胞的极化状态。